Quantcast
Last updated on April 18, 2014 at 7:48 EDT

Latest Macrolide antibiotics Stories

2010-10-15 07:00:00

CHAPEL HILL, N.C., Oct. 15 /PRNewswire/ -- Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia. All presentations are scheduled for 10 a.m. to 6 p.m. PDT on Friday, October 22. Solithromycin (CEM-101) The...

2010-09-09 07:00:00

CHAPEL HILL, N.C., Sept. 9 /PRNewswire/ -- Phase 1 presentations: Provide evidence of the safe administration of multiple oral doses Demonstrate high levels of pulmonary accumulation in the lung that could provide coverage for macrolide-resistant pneumococci Demonstrate no food effect, unlike other macrolides In vivo toxicology and pharmacokinetic studies further define solithromycin's IV and oral safety profile and provide support for dose selection in upcoming clinical trials with...

2010-09-08 07:00:00

CHAPEL HILL, N.C., Sept. 8 /PRNewswire/ -- Cempra Pharmaceuticals announced that it is moving forward in its dual approach to the development of solithromycin (CEM-101), a fluoroketolide which is first of a new generation of macrolide-ketolide antibiotics for treatment of community-acquired bacterial pneumonia (CABP). Patients with CABP are currently being enrolled into a Phase 2 trial evaluating the oral formulation of solithromycin while concurrently a Phase 1 trial with the...

2010-08-10 08:15:00

CHICAGO, Aug. 10 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its...

2010-07-16 12:00:00

CHENGDU, China, July 16 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine and branded generics provides progress update on its Jiangchuan macrolide facility. The construction of the facility is on schedule, targeting August for completion and equipment installation, immediately followed by GMP certification and trial production. The state-of-the-art...

2010-05-18 08:15:00

CHAPEL HILL, N.C., May 18 /PRNewswire/ -- Cempra Pharmaceuticals today announced the results from two poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, at the American Thoracic Society 2010 International Conference, May 14 to 19, 2010, in New Orleans. Both presentations are scheduled for 8:15 a.m. to 4 p.m. CDT on Tuesday, May 18. The two posters by Kobayashi et al. compared the anti-inflammatory activity of CEM-101 to several available macrolide...

2010-05-13 06:00:00

CHAPEL HILL, N.C., May 13 /PRNewswire/ -- Cempra Pharmaceuticals today announced the schedule of poster presentations on its next-generation macrolide, CEM-101, at the American Thoracic Society (ATS) 2010 International Conference in New Orleans, Louisiana, on May 14 to 19, 2010. Both posters will be presented during the poster session entitled "C41 Emerging Pharmacology for Chronic Obstructive Pulmonary Disease: Mechanisms and Outcomes" scheduled for 8:15 a.m. to 4:00 p.m. CDT on Tuesday,...

2010-05-05 12:00:25

Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA. "A vicious cycle of infection and inflammation causes progressive lung destruction and premature death in patients with cystic fibrosis (CF). Treatment strategies have therefore included both antimicrobial and anti-inflammatory agents," the authors write. There has been...

2010-04-10 05:00:00

CHAPEL HILL, N.C., Apr. 10 /PRNewswire/ -- Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 10 to 13, 2010, in Vienna Austria. All presentations are scheduled for 12:30 to 1:30 p.m. CET on Sunday, April 11. CEM-101...

2010-03-11 06:30:00

CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical program required to assess the approvability of Restanza(TM) (cethromycin), a novel oral once-a-day...